Macquarie Group Ltd. lifted its holdings in shares of TESARO Inc (NASDAQ:TSRO) by 48.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 323,748 shares of the biopharmaceutical company’s stock after acquiring an additional 105,753 shares during the quarter. Macquarie Group Ltd. owned 0.59% of TESARO worth $14,397,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC acquired a new position in TESARO in the first quarter worth about $110,000. Ostrum Asset Management acquired a new position in TESARO in the first quarter worth about $111,000. American International Group Inc. grew its stake in TESARO by 138.8% in the first quarter. American International Group Inc. now owns 2,099 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 1,220 shares in the last quarter. Skylands Capital LLC acquired a new position in TESARO in the second quarter worth about $182,000. Finally, Stifel Financial Corp acquired a new position in TESARO in the first quarter worth about $241,000.

TSRO has been the subject of a number of research reports. Guggenheim initiated coverage on TESARO in a research note on Monday, September 17th. They issued a “buy” rating for the company. Bank of America lifted their price target on TESARO from $35.00 to $38.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 11th. Cann reiterated a “buy” rating and issued a $83.00 price target on shares of TESARO in a research note on Tuesday, September 4th. Barclays decreased their price target on TESARO from $60.00 to $56.00 and set an “overweight” rating for the company in a research note on Monday, August 6th. Finally, Citigroup decreased their price target on TESARO from $100.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, August 29th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the stock. TESARO presently has a consensus rating of “Buy” and an average price target of $78.42.

TSRO stock traded up $1.95 during midday trading on Friday, reaching $40.60. The company had a trading volume of 1,670,395 shares, compared to its average volume of 1,578,841. The company has a quick ratio of 3.64, a current ratio of 4.11 and a debt-to-equity ratio of -29.71. TESARO Inc has a fifty-two week low of $25.62 and a fifty-two week high of $125.78. The company has a market cap of $2.14 billion, a P/E ratio of -4.43 and a beta of 1.00.

TESARO (NASDAQ:TSRO) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($3.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.66) by ($0.38). The company had revenue of $57.21 million during the quarter, compared to analyst estimates of $65.50 million. TESARO had a negative net margin of 180.29% and a negative return on equity of 285.30%. The business’s revenue was up 94.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($2.82) earnings per share. Analysts expect that TESARO Inc will post -11.12 EPS for the current fiscal year.

In other news, Director Arnold L. Oronsky sold 10,000 shares of TESARO stock in a transaction that occurred on Tuesday, August 7th. The stock was sold at an average price of $26.77, for a total transaction of $267,700.00. Following the sale, the director now owns 12,479 shares of the company’s stock, valued at $334,062.83. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 10,630 shares of company stock worth $290,424. Corporate insiders own 33.70% of the company’s stock.

TESARO Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Story: New Google Finance Tool and Screening Stocks

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.